Anavex Life Sciences Corp (AVXL)

[Gernee20]

Missling is a collaborator. He doesn’t need to do it all himself. He has partnered with 3-4 foundations and multiple universities/institutions to foot the bill for Anavex’s preclinical studies, and in turn, build and justify a case to regulatory authorities to move forward with our 3 indications. The guy now has 6 ongoing trials, 3 of which are pivotal, and 1 of which is for the largest unmet need and most costly and detrimental to our healthcare system. The big boys all spend billions, but not Anavex. Anavex has learned through watching the failures. Missling doesn’t need to fail in order to learn and improve.he learns from others and their mistakes, and by others I mean all those smart folks working for BP. He has taken all the tools and tricks for quicker drug development from the oncology field and slapped CNS right in the face with it. Applying oncology PM to CNS has never been done before, believe it or not. It’s called innovation and thinking outside of the stubborn, FDA box. He took 5 trials to Australia, of which, half the costs are being reimbursed by the Aussie government. He has collaborated with 8 companies in hopes to advance science thru the potential of ERP biomarkers, first up is schizophrenia. Other indications will be added, and promising compounds within the Consortium will then go to clinical trials. Do you think Anavex will be footing the bill? No, they won’t. Merck and the other cash fat members will.

It’s not about who spends the most money. It’s about who has the foresight, preparation and ability to apply the most successful and scientific approaches to CNS drug development. Conduct trials to fail fast, so you can move on from lackluster compounds and MOAs as quickly as possible. This is precisely what BP has not done. BP has too much money to be innovative and efficient. Their way of life are huge trials, costing hundreds of millions, without any idea whether the trial will yield anything positive. I just posted an article coming out of CTAD. Read it (see link below). The article is an excellent read, as it is directing the AD field to smaller phase 2’s, adaptive trials with AI, genetic biomarkers and variability and mastering (as much as possible) compounds and their MOA. They literally describe Anavex. The best part is, Anavex has been following this recommended protocol for the last 5-6 years. I guess it’s nice to know they are that far ahead of the rest of the field lol. You don’t need to argue with all the delusional folks on this board, contact CTAD, the 2nd largest Alzheimer’s conference in the world and argue with them.

https://www.alzforum.org/news/conference-coverage/ctad-lessons-2020-more-phase-2-trials-more-diversity